Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15157756 | 0.86 | BACE1 (0.34) | BACE1BACE2 | |
| SCHEMBL7938915 | 0.83 | BACE1 (0.35) | BACE1BACE2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7940166 | 0.82 | BACE1 (0.43) | BACE1BACE2 | |
| SCHEMBL1992787 | 0.76 | BACE1 (0.48) | BACE1 | |
| SCHEMBL7934145 | 0.70 | BACE1 (0.38) | BACE1BACE2 | |
| Formic Acid SCHEMBL1993138 | 0.69 | — | — | |
| SCHEMBL7943032 | 0.68 | SIRT2 (0.38) | BACE1BACE2 | |
| SCHEMBL7934136 | 0.68 | BACE1 (0.34) | BACE1BACE2 | |
| Formic Acid SCHEMBL15157408 | 0.67 | ADRA2A (0.32) | BACE1 | |
| SCHEMBL1991286 | 0.65 | BACE1 (0.57) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152253-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152253-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CYP1A2 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.